SCHOTT has announced that it plans to achieve further growth in its prefillable syringe line.
Dr Jürgen Sackhoff, executive vice-president of SCHOTT Pharmaceutical Systems, underscores the group’s commitment to provide pharmaceutical companies with best-in-class solutions.
"It has always been our strategy to engage in an open dialogue with our customers," he said. "Integrating with their processes enables us to find the best solution. Customers can rest assured that we will round off our full portfolio with further innovations in the future."
To highlight SCHOTT’s commitment, especially in the area of prefillable glass syringes, the company launched a new brand to resonate this new vision. All glass syringes are now to be marketed under the umbrella of the new brand name syriQ(TM).
SCHOTT has been manufacturing glass and polymer syringes in Europe and the US for more than 12 years. The production facility in St Gallen, Switzerland, has developed into a centre of excellence and is supported by an R&D team based at the site. A large annual production capacity ensures security of supply – with infrastructure available for further expansion. Just recently, SCHOTT doubled its production capacities for TopPac polymer syringes.
To offer pharmaceutical companies a broad range of solutions, SCHOTT has a complete portfolio of both glass and polymer syringes. In the field of glass syringes, the offerings range from 0.5ml to 3ml products, suitable for a broad variety of applications such as heparin, vaccines, biotech, and special applications.
With regard to polymer syringes, the company has completed its portfolio of large volume syringes for intensive care which now includes the entire range of 10ml, 20ml, and 50ml formats.